{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 42,
        "end": 50
      }
    },
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 65,
        "end": 71
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 82,
        "end": 86
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 115,
        "end": 130
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 139,
        "end": 149
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "27027150_2",
  "text": "INTRODUCTION : In the 40-50 % of advanced melanoma patients with tumors harboring BRAF V600E and V600K mutations , BRAF inhibitors such as dabrafenib are a highly effective treatment ."
}
